Skip to main content

Table 1 Clinical characteristics of patients receiving Convalescent Plasma Therapy

From: Effectiveness of convalescent plasma therapy in eight non-intubated coronavirus disease 2019 patients in Indonesia: a case series

No. Patient Sex Age (years) Stage of disease Days from symptom onset to admission Days from symptom onset to CPT Site of infection Main symptoms Comorbidities
1 SUN M 50 Severe COVID-19 5 9 Lung Fever, cough, dyspnea Hypertension, diabetes mellitus type 2, anxiety disorder
2 HSD M 67 Severe COVID-19 7 16 Lung Fever, cough, nausea, dyspnea CAD post PCI, diabetes mellitus type 2, hypertension
3 YHA F 50 Severe COVID-19 7 13 Lung Dyspnea, fever, cough, diarrhea None
4 AMH F 45 Severe COVID-19 4 10 Lung Dyspnea, fever, cough, myalgia Diabetes mellitus type 2
5 ERN M 55 Severe COVID-19 7 15 Lung Dyspnea, cough, fever Diabetes mellitus type 2
6 DSO M 40 Severe COVID-19 3 11 Lung Dyspnea, fever, fatigue, nausea None
7 RMD M 51 Severe COVID-19 5 11 Lung Fever, diarrhea Polycythemia vera
8 HUM F 74 Severe COVID-19 14 19 Lung Nausea, general weakness, dyspnea Diabetes mellitus type 2, arrhythmia (frequent VES)
  1. CAD: Coronary Artery Disease, PCI: Percutaneous Coronary intervention, VES: Ventricular Extra Systole, CPT: Convalescent Plasma Therapy, CAD: Coronary Artery Disease, PCI: Percutaneous Coronary intervention, VES: Ventricular Extra Systole